Comparing Caplyta vs Cobenfy
| Caplyta (lumateperone) | Cobenfy (trospium / xanomeline) |
|
|---|
| Caplyta (lumateperone) | Cobenfy (trospium / xanomeline) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Caplyta is an atypical antipsychotic that is used to treat adults with schizophrenia or depression associated with bipolar disorder. Sleepiness is the most common side effect and it should not be... View more |
Prescription only
Prescribed for Schizophrenia. Cobenfy may also be used for purposes not listed in this medication guide. |
Related suggestions Schizophrenia
Popular comparisons
|
|||||||||||||||
| More about Caplyta (lumateperone) | More about Cobenfy (trospium / xanomeline) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Caplyta has an average rating of 6.6 out of 10 from a total of 184 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 29% reported a negative effect. |
Cobenfy has an average rating of 6.0 out of 10 from a total of 4 ratings on Drugs.com. 25% of reviewers reported a positive effect, while 25% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Caplyta side effects |
View all Cobenfy side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Caplyta prices |
View all Cobenfy prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
18 hours |
6 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 605 drugs are known to interact with Caplyta:
|
A total of 386 drugs are known to interact with Cobenfy:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
December 20, 2019 |
September 26, 2024 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.